tetano
Editor, Senior Moderator
NPJ Vaccines
. 2021 Feb 26;6(1):30.
doi: 10.1038/s41541-021-00295-7.
Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses
Peter Radvak[SUP] 1 [/SUP], Martina Kosikova[SUP] 1 [/SUP], Yuan-Chia Kuo[SUP] 1 [/SUP], Xing Li[SUP] 1 [/SUP], Richard Garner[SUP] 1 [/SUP], Falko Schmeisser[SUP] 2 [/SUP], Ivan Kosik[SUP] 3 [/SUP], Zhiping Ye[SUP] 1 [/SUP], Jerry P Weir[SUP] 2 [/SUP], Jonathan W Yewdell[SUP] 3 [/SUP], Hang Xie[SUP] 4 [/SUP]
Affiliations
Abstract
Avian influenza A(H7N9) epidemics have a fatality rate of approximately 40%. Previous studies reported that low pathogenic avian influenza (LPAI)-derived candidate vaccine viruses (CVVs) are poorly immunogenic. Here, we assess the immunogenicity and efficacy of a highly pathogenic avian influenza (HPAI) A/Guangdong/17SF003/2016 (GD/16)-extracted hemagglutinin (eHA) vaccine. GD/16 eHA induces robust H7-specific antibody responses in mice with a marked adjuvant antigen-sparing effect. Mice immunized with adjuvanted GD/16 eHA are protected from the lethal LPAI and HPAI H7N9 challenges, in stark contrast to low antibody titers and high mortality in mice receiving adjuvanted LPAI H7 eHAs. The protection correlates well with the magnitude of the H7-specific antibody response (IgG and microneutralization) or HA group 2 stem-specific IgG. Inclusion of adjuvanted GD/16 eHA in heterologous prime-boost improves the immunogenicity and protection of LPAI H7 HAs in mice. Our findings support the inclusion of GD/16-derived CVV in the pandemic preparedness vaccine stockpile.
. 2021 Feb 26;6(1):30.
doi: 10.1038/s41541-021-00295-7.
Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses
Peter Radvak[SUP] 1 [/SUP], Martina Kosikova[SUP] 1 [/SUP], Yuan-Chia Kuo[SUP] 1 [/SUP], Xing Li[SUP] 1 [/SUP], Richard Garner[SUP] 1 [/SUP], Falko Schmeisser[SUP] 2 [/SUP], Ivan Kosik[SUP] 3 [/SUP], Zhiping Ye[SUP] 1 [/SUP], Jerry P Weir[SUP] 2 [/SUP], Jonathan W Yewdell[SUP] 3 [/SUP], Hang Xie[SUP] 4 [/SUP]
Affiliations
- PMID: 33637737
- DOI: 10.1038/s41541-021-00295-7
Abstract
Avian influenza A(H7N9) epidemics have a fatality rate of approximately 40%. Previous studies reported that low pathogenic avian influenza (LPAI)-derived candidate vaccine viruses (CVVs) are poorly immunogenic. Here, we assess the immunogenicity and efficacy of a highly pathogenic avian influenza (HPAI) A/Guangdong/17SF003/2016 (GD/16)-extracted hemagglutinin (eHA) vaccine. GD/16 eHA induces robust H7-specific antibody responses in mice with a marked adjuvant antigen-sparing effect. Mice immunized with adjuvanted GD/16 eHA are protected from the lethal LPAI and HPAI H7N9 challenges, in stark contrast to low antibody titers and high mortality in mice receiving adjuvanted LPAI H7 eHAs. The protection correlates well with the magnitude of the H7-specific antibody response (IgG and microneutralization) or HA group 2 stem-specific IgG. Inclusion of adjuvanted GD/16 eHA in heterologous prime-boost improves the immunogenicity and protection of LPAI H7 HAs in mice. Our findings support the inclusion of GD/16-derived CVV in the pandemic preparedness vaccine stockpile.